Icon Wealth Advisors LLC Acquires Shares of 2,362 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Icon Wealth Advisors LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,362 shares of the company's stock, valued at approximately $1,193,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Trust N.A. grew its holdings in shares of IDEXX Laboratories by 67.3% during the 3rd quarter. Raymond James Trust N.A. now owns 3,879 shares of the company's stock worth $1,960,000 after purchasing an additional 1,561 shares during the period. Pacer Advisors Inc. lifted its position in IDEXX Laboratories by 14.4% in the third quarter. Pacer Advisors Inc. now owns 13,742 shares of the company's stock valued at $6,943,000 after buying an additional 1,729 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in IDEXX Laboratories by 4.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 406,086 shares of the company's stock worth $205,163,000 after buying an additional 15,521 shares during the period. Integrated Investment Consultants LLC increased its position in shares of IDEXX Laboratories by 48.4% during the third quarter. Integrated Investment Consultants LLC now owns 650 shares of the company's stock valued at $328,000 after acquiring an additional 212 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of IDEXX Laboratories by 4.8% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 73,477 shares of the company's stock valued at $37,122,000 after acquiring an additional 3,382 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Down 0.3 %

Shares of IDXX traded down $1.31 during midday trading on Friday, hitting $417.24. The company had a trading volume of 503,442 shares, compared to its average volume of 775,938. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The firm has a market capitalization of $34.17 billion, a P/E ratio of 40.24, a P/E/G ratio of 3.65 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The company's 50-day simple moving average is $460.86 and its 200-day simple moving average is $480.70.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million during the quarter, compared to analysts' expectations of $980.32 million. During the same quarter in the previous year, the business posted $2.53 EPS. The firm's revenue was up 6.6% on a year-over-year basis. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research report on Thursday, October 10th. JPMorgan Chase & Co. lowered their price target on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Piper Sandler reiterated a "neutral" rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, Barclays decreased their target price on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.